{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:47:35Z","timestamp":1788961655603,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04364-5","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:56:28Z","timestamp":1775490988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hypoalbuminemia induces immunosuppression through disorder in macrophages and drives resistance to immune checkpoint inhibitors"],"prefix":"10.1007","volume":"75","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"4364_CR1","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1200\/jco.2016.66.9861","volume":"34","author":"NA Rizvi","year":"2016","unstructured":"Rizvi NA, Hellmann MD, Brahmer JR et al (2016) Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 34:2969\u20132979. https:\/\/doi.org\/10.1200\/jco.2016.66.9861","journal-title":"J Clin Oncol"},{"key":"4364_CR2","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/s1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1480\u20131492. https:\/\/doi.org\/10.1016\/s1470-2045(18)30700-9","journal-title":"Lancet Oncol"},{"key":"4364_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2017.11.016","volume":"73","author":"T Powles","year":"2018","unstructured":"Powles T, Albiges L, Staehler M et al (2018) Updated European Association of Urology guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol 73:311\u2013315. https:\/\/doi.org\/10.1016\/j.eururo.2017.11.016","journal-title":"Eur Urol"},{"key":"4364_CR4","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/jco.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G et al (2023) Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol 41:1992\u20131998. https:\/\/doi.org\/10.1200\/jco.22.01989","journal-title":"J Clin Oncol"},{"key":"4364_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/jco.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A et al (2023) Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol 41:1999\u20132006. https:\/\/doi.org\/10.1200\/jco.22.01990","journal-title":"J Clin Oncol"},{"key":"4364_CR6","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, Mezquita L, Texier M et al (2018) Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 4:1543\u20131552. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3676","journal-title":"JAMA Oncol"},{"key":"4364_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1136","volume":"4","author":"HJ Park","year":"2021","unstructured":"Park HJ, Kim KW, Won SE, Yoon S, Chae YK, Tirumani SH, Ramaiya NH (2021) Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Netw Open 4:e211136. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.1136","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4364_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398","volume":"8","author":"HM Kluger","year":"2020","unstructured":"Kluger HM, Tawbi HA, Ascierto ML et al (2020) Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer 8(1):e000398. https:\/\/doi.org\/10.1136\/jitc-2019-000398","journal-title":"J Immunother Cancer"},{"issue":"12","key":"4364_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005670","volume":"10","author":"M Zheng","year":"2022","unstructured":"Zheng M (2022) Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade. J Immunother Cancer 10(12):e005670. https:\/\/doi.org\/10.1136\/jitc-2022-005670","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4364_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001674","volume":"8","author":"P Johannet","year":"2020","unstructured":"Johannet P, Sawyers A, Qian Y, Kozloff S, Gulati N, Donnelly D, Zhong J, Osman I (2020) Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. J Immunother Cancer 8(2):e001674. https:\/\/doi.org\/10.1136\/jitc-2020-001674","journal-title":"J Immunother Cancer"},{"key":"4364_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03070-x","volume":"23","author":"Y Long","year":"2023","unstructured":"Long Y, Yang W, Bai Y et al (2023) Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study. Cancer Cell Int 23:224. https:\/\/doi.org\/10.1186\/s12935-023-03070-x","journal-title":"Cancer Cell Int"},{"key":"4364_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35317-y","volume":"13","author":"G Hu","year":"2022","unstructured":"Hu G, Ling C, Chi L et al (2022) The role of the tryptophan-NAD\u2009+\u2009pathway in a mouse model of severe malnutrition induced liver dysfunction. Nat Commun 13:7576. https:\/\/doi.org\/10.1038\/s41467-022-35317-y","journal-title":"Nat Commun"},{"key":"4364_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/hep.0000000000000521","volume":"81","author":"J Trebicka","year":"2025","unstructured":"Trebicka J, Garcia-Tsao G (2025) Controversies regarding albumin therapy in cirrhosis. Hepatology 81:288\u2013303. https:\/\/doi.org\/10.1097\/hep.0000000000000521","journal-title":"Hepatology"},{"key":"4364_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/hep.28897","volume":"65","author":"S Das","year":"2017","unstructured":"Das S, Maras JS, Hussain MS et al (2017) Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis. Hepatology 65:631\u2013646. https:\/\/doi.org\/10.1002\/hep.28897","journal-title":"Hepatology"},{"key":"4364_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jconrel.2025.01.035","volume":"380","author":"G Murphy","year":"2025","unstructured":"Murphy G, Brayden DJ, Cheung DL, Liew A, Fitzgerald M, Pandit A (2025) Albumin-based delivery systems: recent advances, challenges, and opportunities. J Control Release 380:375\u2013395. https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.035","journal-title":"J Control Release"},{"key":"4364_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/ejhf.3363","volume":"27","author":"M Biancucci","year":"2025","unstructured":"Biancucci M, Barbiero R, Pennella B, Cannata A, Ageno W, Tangianu F, Maresca AM, Dentali F, Bonaventura A (2025) Hypoalbuminaemia and heart failure: a practical review of current evidence. Eur J Heart Fail 27:293\u2013306. https:\/\/doi.org\/10.1002\/ejhf.3363","journal-title":"Eur J Heart Fail"},{"key":"4364_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa2022166","volume":"384","author":"L China","year":"2021","unstructured":"China L, Freemantle N, Forrest E et al (2021) A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med 384:808\u2013817. https:\/\/doi.org\/10.1056\/NEJMoa2022166","journal-title":"N Engl J Med"},{"key":"4364_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1681\/asn.2021060751","volume":"33","author":"KA Lidberg","year":"2022","unstructured":"Lidberg KA, Muthusamy S, Adil M et al (2022) Serum protein exposure activates a core regulatory program driving human proximal tubule injury. J Am Soc Nephrol 33:949\u2013965. https:\/\/doi.org\/10.1681\/asn.2021060751","journal-title":"J Am Soc Nephrol"},{"key":"4364_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892534","volume":"13","author":"ES Ward","year":"2022","unstructured":"Ward ES, Gelinas D, Dreesen E et al (2022) Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders. Front Immunol 13:892534. https:\/\/doi.org\/10.3389\/fimmu.2022.892534","journal-title":"Front Immunol"},{"key":"4364_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","volume":"82","author":"O Bouillanne","year":"2005","unstructured":"Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, Benazeth S, Cynober L, Aussel C (2005) Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr 82:777\u2013783. https:\/\/doi.org\/10.1093\/ajcn\/82.4.777","journal-title":"Am J Clin Nutr"},{"key":"4364_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000541647","volume":"14","author":"H Nam","year":"2025","unstructured":"Nam H, Sung PS, Lee SW, Song DS, Kwon JH, Jang JW, Kim CW, Bae SH (2025) Incorporating ALBI grade with geriatric nutritional risk index enhances hepatocellular carcinoma risk stratification. Liver Cancer 14:193\u2013210. https:\/\/doi.org\/10.1159\/000541647","journal-title":"Liver Cancer"},{"key":"4364_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002851","author":"JT Brown","year":"2021","unstructured":"Brown JT, Liu Y, Shabto JM et al (2021) Modified Glasgow prognostic score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002851","journal-title":"J Immunother Cancer"},{"key":"4364_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/jco.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550\u2013558. https:\/\/doi.org\/10.1200\/jco.2014.57.9151","journal-title":"J Clin Oncol"},{"key":"4364_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000529996","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M, Finn RS, Cheng AL et al (2023) Albumin-bilirubin grade analyses of Atezolizumab plus Bevacizumab versus Sorafenib in patients with unresectable hepatocellular carcinoma: a post hoc analysis of the Phase III IMbrave150 study. Liver Cancer 12:479\u2013493. https:\/\/doi.org\/10.1159\/000529996","journal-title":"Liver Cancer"},{"key":"4364_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adh2284","volume":"9","author":"TN Phiri","year":"2023","unstructured":"Phiri TN, Mutasa K, Rukobo S et al (2023) Severe acute malnutrition promotes bacterial binding over proinflammatory cytokine secretion by circulating innate immune cells. Sci Adv 9:eadh2284. https:\/\/doi.org\/10.1126\/sciadv.adh2284","journal-title":"Sci Adv"},{"key":"4364_CR26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1128\/cmr.00119-16","volume":"30","author":"MK Ibrahim","year":"2017","unstructured":"Ibrahim MK, Zambruni M, Melby CL, Melby PC (2017) Impact of childhood malnutrition on host defense and infection. Clin Microbiol Rev 30:919\u2013971. https:\/\/doi.org\/10.1128\/cmr.00119-16","journal-title":"Clin Microbiol Rev"},{"key":"4364_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/s2468-1253(23)00011-0","volume":"8","author":"S Massironi","year":"2023","unstructured":"Massironi S, Vigano C, Palermo A, Pirola L, Mulinacci G, Allocca M, Peyrin-Biroulet L, Danese S (2023) Inflammation and malnutrition in inflammatory bowel disease. Lancet Gastroenterol Hepatol 8:579\u2013590. https:\/\/doi.org\/10.1016\/s2468-1253(23)00011-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4364_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-022-01437-2","volume":"10","author":"Y Huang","year":"2022","unstructured":"Huang Y, Lu W, Zeng M et al (2022) Mapping the early life gut microbiome in neonates with critical congenital heart disease: multiomics insights and implications for host metabolic and immunological health. Microbiome 10:245. https:\/\/doi.org\/10.1186\/s40168-022-01437-2","journal-title":"Microbiome"},{"key":"4364_CR29","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","volume":"24","author":"TR Flint","year":"2016","unstructured":"Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT (2016) Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab 24:672\u2013684. https:\/\/doi.org\/10.1016\/j.cmet.2016.10.010","journal-title":"Cell Metab"},{"key":"4364_CR30","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.trecan.2023.06.003","volume":"9","author":"CL McIntyre","year":"2023","unstructured":"McIntyre CL, Temesgen A, Lynch L (2023) Diet, nutrient supply, and tumor immune responses. Trends Cancer 9:752\u2013763. https:\/\/doi.org\/10.1016\/j.trecan.2023.06.003","journal-title":"Trends Cancer"},{"key":"4364_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22652-9","volume":"12","author":"CL Chen","year":"2021","unstructured":"Chen CL, Hsu SC, Chung TY et al (2021) Arginine is an epigenetic regulator targeting TEAD4 to modulate OXPHOS in prostate cancer cells. Nat Commun 12:2398. https:\/\/doi.org\/10.1038\/s41467-021-22652-9","journal-title":"Nat Commun"},{"key":"4364_CR32","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1016\/j.cell.2023.09.011","volume":"186","author":"D Mossmann","year":"2023","unstructured":"Mossmann D, Muller C, Park S et al (2023) Arginine reprograms metabolism in liver cancer via RBM39. Cell 186:5068\u201383.e23. https:\/\/doi.org\/10.1016\/j.cell.2023.09.011","journal-title":"Cell"},{"key":"4364_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03066-6","volume":"9","author":"KEJ Jungnickel","year":"2018","unstructured":"Jungnickel KEJ, Parker JL, Newstead S (2018) Structural basis for amino acid transport by the CAT family of SLC7 transporters. Nat Commun 9:550. https:\/\/doi.org\/10.1038\/s41467-018-03066-6","journal-title":"Nat Commun"},{"key":"4364_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade9120","volume":"9","author":"DJ Hsu","year":"2023","unstructured":"Hsu DJ, Gao J, Yamaguchi N et al (2023) Arginine limitation drives a directed codon-dependent DNA sequence evolution response in colorectal cancer cells. Sci Adv 9:eade9120. https:\/\/doi.org\/10.1126\/sciadv.ade9120","journal-title":"Sci Adv"},{"key":"4364_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010094","author":"LX Ma","year":"2024","unstructured":"Ma LX, Titmuss E, Loree JM et al (2024) Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-010094","journal-title":"J Immunother Cancer"},{"key":"4364_CR36","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.annonc.2022.07.001","volume":"33","author":"F Peyraud","year":"2022","unstructured":"Peyraud F, Gu\u00e9gan JP, Bodet D et al (2022) Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. Ann Oncol 33:1041\u20131051. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.001","journal-title":"Ann Oncol"},{"key":"4364_CR37","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ccell.2025.03.015","volume":"43","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Zhou Z, Du X et al (2025) Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion. Cancer Cell 43:1045\u201360.e7. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.015","journal-title":"Cancer Cell"},{"key":"4364_CR38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/gutjnl-2024-333020","volume":"74","author":"K Nan","year":"2025","unstructured":"Nan K, Zhong Z, Yue Y et al (2025) Fasting-mimicking diet-enriched Bifidobacterium pseudolongum suppresses colorectal cancer by inducing memory CD8(+) T cells. Gut 74:775\u2013786. https:\/\/doi.org\/10.1136\/gutjnl-2024-333020","journal-title":"Gut"},{"key":"4364_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc4275","author":"R Wu","year":"2020","unstructured":"Wu R, Chen X, Kang S et al (2020) De novo synthesis and salvage pathway coordinately regulate polyamine homeostasis and determine T cell proliferation and function. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.abc4275","journal-title":"Sci Adv"},{"key":"4364_CR40","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.ccell.2025.04.004","volume":"43","author":"I Vogel","year":"2025","unstructured":"Vogel I, Bapat SP (2025) Taming immunity through an unexpected source. Cancer Cell 43:1002\u20131004. https:\/\/doi.org\/10.1016\/j.ccell.2025.04.004","journal-title":"Cancer Cell"},{"key":"4364_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2073132","volume":"14","author":"YJ Kim","year":"2022","unstructured":"Kim YJ, Lee JY, Lee JJ et al (2022) Arginine-mediated gut microbiome remodeling promotes host pulmonary immune defense against nontuberculous mycobacterial infection. Gut Microbes 14:2073132. https:\/\/doi.org\/10.1080\/19490976.2022.2073132","journal-title":"Gut Microbes"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04364-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04364-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04364-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:56:29Z","timestamp":1775490989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04364-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4364"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04364-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The retrospective study was approved by ethics committee of the PLA General Hospital following the Declaration of Helsinki and its subsequent revisions (No. S2023-121\u201301). Written informed consent was obtained from all participants. All animal procedures were performed in accordance with the conditions approved by ethics committee of the Chinese PLA General Hospital (No. IACUC-DWZX-2023\u2013524).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"137"}}